Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma

David Böckle, MD, Paula Tabares Gaviria, Xiang Zhou, MD, Janin Messerschmidt, MD, Lukas Scheller, Maximilian Johannes Steinhardt, MD, Elena Seebacher, Maria Ulbrich, Anke Heidemeier, MD, Andreas Buck, MD, Hermann Einsele, MD, Andreas Beilhack, MD, Martin Kortuem, MD, Leo Rasche, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140772

Published: 2020

Journal Articles

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

Blood (2019) 134 (Supplement_1): 855.

https://doi.org/10.1182/blood-2019-126674

Published: 2019

Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1277.

https://doi.org/10.1182/blood-2019-129762

Published: 2019

Journal Articles

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Santiago Barrio, PhD, Larissa Haertle, PhD, Umair Munawar, MSc, Lucia Martin, Isabel Cuenca, MSc, Cornelia Vogt, MSc, Andoni Garitano-Trojaola, PhD, Matteo Claudio Da Via', MD, Miguel Gallardo, PhD, Thorsten Stuehmer, PhD, Hermann Einsele, MD, Leo Rasche, MD, Joaquin Martinez-Lopez, MD PhD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 1807.

https://doi.org/10.1182/blood-2019-130812

Published: 2019

Journal Articles

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Larissa Haertle, PhD, Santiago Barrio, PhD, Michal Simicek, PhD, Umair Munawar, MSc, Ricardo Sanchez, PhD MD, Max Bittrich, MD, Matteo DaVia, MD, Cornelia Vogt, MSc, Nicola Giesen, MD, Andoni Garitano-Trojaola, PhD, Silvia Nerreter, Thorsten Stuehmer, PhD, Marc S. Raab, MD, Joaquin Martinez Lopez, MD PhD, Roman Hajek, MD, Hermann Einsele, MD, Leo Rasche, MD, Thomas Haaf, MD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 4349.

https://doi.org/10.1182/blood-2019-130847

Published: 2019

Journal Articles

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

Faith E. Davies, MD, Rohan Samant, MD, Thomas J. Eluvathingal, Leo Rasche, MD, Amy Buros, PhD, Kristen Schemel, Edgardo J. Angtuaco, MD, Rudy L. Van Hemert, MD, Manoj Kumar, MD, James E McDonald, BS, MD, James A. Ntambi, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Niels Weinhold, PhD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 5375.

https://doi.org/10.1182/blood.V130.Suppl_1.5375.5375

Published: 2017

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

Journal Articles

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Leo Rasche, MD, Carolina D. Schinke, MD, Daisy Alapat, MD, Grant Gershner, Sarah K Johnson, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, James E McDonald, BS, MD, Rohan Samant, MD, Edgardo Angtuaco, MD, Brian A Walker, PhD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4510.

https://doi.org/10.1182/blood.V130.Suppl_1.4510.4510

Published: 2017

Journal Articles

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Leo Rasche, MD, Tobias Meissner, PhD, Grant Gershner, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Owen W. Stephens, Michael Bauer, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4372.

https://doi.org/10.1182/blood.V130.Suppl_1.4372.4372

Published: 2017

Journal Articles

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Meera Mohan, MD, Niels Weinhold, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Leo Rasche, MD, Jeffery R. Sawyer, Erming Tian, PhD MBA, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Maurizio Zangari, MD

Blood (2017) 130 (Supplement 1): 4373.

https://doi.org/10.1182/blood.V130.Suppl_1.4373.4373

Published: 2017

Journal Articles

Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions

Cody Cody Ashby, PhD, Michael Bauer, PhD, Owen W. Stephens, Christopher P. Wardell, PhD, Ruslana G. Tytarenko, MS, Aneta Mikulasova, PhD, Purvi Patel, Shayu Deshpande, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Niels Weinhold, PhD, Leo Rasche, MD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 3032.

https://doi.org/10.1182/blood.V130.Suppl_1.3032.3032

Published: 2017

Journal Articles

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Sharmilan Thanendrarajan, MD, Jerry Puryear, PharmD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Pankaj Mathur, MD, Meera Mohan, MD, Sandra Susanibar, MD, Jorge Jo Kamimoto, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Leo Rasche, MD, Niels Weinhold, PhD, Brian A Walker, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 1858.

https://doi.org/10.1182/blood.V130.Suppl_1.1858.1858

Published: 2017

Journal Articles

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

Blood (2016) 128 (22): 4416.

https://doi.org/10.1182/blood.V128.22.4416.4416

Published: 2016

Journal Articles

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Leo Rasche, MD, Amy Buros, PhD, Niels Weinhold, PhD, Caleb K. Stein, MS, James E McDonald, Shweta S. Chavan, PhD, Edgardo Angtuaco, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4431.

https://doi.org/10.1182/blood.V128.22.4431.4431

Published: 2016

Journal Articles

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Antonio Branca, MD, Amy Buros, PhD, Donghoon Yoon, PhD, Larry J Suva, PhD, Niels Weinhold, PhD, Leo Rasche, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Cerisse Harcourt, APRN, OCN, Faith E Davies, MD, Frits van Rhee, MD PhD, Gareth J Morgan, MD PhD, Maurizio Zangari, MD

Blood (2016) 128 (22): 4516.

https://doi.org/10.1182/blood.V128.22.4516.4516

Published: 2016

Journal Articles

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Blood (2016) 128 (22): 117.

https://doi.org/10.1182/blood.V128.22.117.117

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Blood (2016) 128 (22): 3278.

https://doi.org/10.1182/blood.V128.22.3278.3278

Published: 2016

Journal Articles

Spatial-Temporal Genomic Analyses Reveal a Component of "Big Bang" Kinetics in Multiple Myeloma Evolution

Niels Weinhold, PhD, Leo Rasche, MD, Tobias Meissner, PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 239.

https://doi.org/10.1182/blood.V128.22.239.239

Published: 2016

Journal Articles

Crucial Role of Regulatory T Cells in Predicting the Outcome of the T Cell Engaging Antibody Blinatumomab in Relapsed and Refractory B Precursor ALL Patients

Johannes Duell, MD, Marcus Dittrich, MD PhD, Tanja Bedke, Tobias Mueller, MD PhD, Leo Rasche, MD, Thomas Dandekar, MD, Hermann Einsele, MD, Max S. Topp, MD

Blood (2014) 124 (21): 2291.

https://doi.org/10.1182/blood.V124.21.2291.2291

Published: 2014

NARROW

Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Spatial-Temporal Genomic Analyses Reveal a Component of "Big Bang" Kinetics in Multiple Myeloma Evolution

Crucial Role of Regulatory T Cells in Predicting the Outcome of the T Cell Engaging Antibody Blinatumomab in Relapsed and Refractory B Precursor ALL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only